Cepeda M.
159
Coauthors
9
Documentos
Volumen de publicaciones por año
Cargando gráfico
| Año de publicación | Num. Publicaciones |
|---|---|
| 2012 | 2 |
| 2014 | 1 |
| 2016 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 1 |
Publicaciones por áreas de conocimiento
Cargando gráfico
| Área de conocimiento | Num. Publicaciones |
|---|---|
| Inmunología | 8 |
| Cáncer | 6 |
| Medicina interna | 1 |
| Infección | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
| Área temática | Num. Publicaciones |
|---|---|
| Enfermedades | 8 |
| Farmacología y terapéutica | 6 |
| Medicina y salud | 3 |
| Microorganismos, hongos y algas | 2 |
| Problemas sociales y servicios a grupos | 1 |
| Ginecología, obstetricia, pediatría, geriatría | 1 |
Principales fuentes de datos
| Origen | Num. Publicaciones |
|---|---|
| Scopus | 9 |
| Google Scholar | 0 |
| RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
| Coautor | Num. Publicaciones |
|---|---|
| Tania Crombet | 6 |
| Mazorra Z. | 5 |
| Lorenzo G. | 5 |
| Pérez K. | 4 |
| De La Torre A.V. | 4 |
| Carmen Elena Viada | 4 |
| Leon K. | 4 |
| Caballero A. | 4 |
| Saavedra Hernández D. | 4 |
| Ortiz R.A. | 3 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
NGlycolylGM3/VSSP vaccine in metastatic breast cancer patients: Results of phase I/IIa clinical trial
ArticleAbstract: Patients treated with vaccines based on NGlycolil gangliosides have showed benefit in progression frPalabras claves:Clinical trial, Ganglioside, Metastatic breast cancer, NGcGM3, Therapeutic vaccineAutores:Arboláez M., Car A., Carmen Elena Viada, Cepeda M., De La Torre A.V., Fernandez L.E., García E., Guerra P.P., Hernandez J., Ortiz R.A., Pérez K., Toledo D.Fuentes:scopusEffect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma
ArticleAbstract: NeuGc-containing gangliosides have been described in melanoma cells and are an attractive target forPalabras claves:Clinical trial, Ganglioside, melanoma, N-glycolyl GM3, Therapeutic vaccineAutores:Ávila Y., Carmen Elena Viada, Carr A., Cepeda M., De La Torre A.V., Fernandez L.E., Gracia E., Hernandez J., Osorio M., Pérez K., Reigosa E., Rodríguez M., Saurez G.Fuentes:scopusAn anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: Report of three cases
ArticleAbstract: In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the diPalabras claves:CD6 molecule, coronavirus 2, covid-19, cytokine-release syndrome, IL-6, Itolizumab, Monoclonal antibody, SARS-COV-2Autores:Añe-Kouri A.L., Berrio J., Caballero A., Caballero J.A., Cepeda M., Cervantes J.B., Figueredo C., Filgueira L.M., Herrera C., Leon K., Lorenzo G., Lovelle O.A., Mazorra Z., Ramos M., Saavedra Hernández D., Sánchez N., Tania CrombetFuentes:scopusAn anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients
ArticleAbstract: Background: Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around thePalabras claves:covid-19, Cytokine release syndrome, IL-6, ItolizumabAutores:Añe-Kouri A.L., Betancourt J., Caballero A., Cepeda M., Chávez E., Filgueira L.M., Herrera C., Hidalgo C.J., Leon K., Lorenzo G., Manso L., Mazorra Z., Ramos M., Saavedra Hernández D., Sánchez N., Tania Crombet, Valenzuela-Silva C.M.Fuentes:scopusMulticentre oncology clinical trials in primary health care in Cuba: evaluation of programme implementation in Villa Clara Province, 2010–2020
ArticleAbstract: Background: The Center of Molecular Immunology of Cuba has developed a programme for the conductingPalabras claves:clinical trials, General practitioners, immunotherapy, neoplasms, Oncology, Primary Health Care, primary healthcareAutores:Artiles M., Cepeda M., Crespo J.C., de la Barca N.d.C., González A., Granela M.C., Lage Davila A., Lorenzo G., Marrero R., Méndez R., Nieto L., Norvel M., Ortiz R.A., Rodríguez M., Sánchez L., Tania Crombet, Toledo E., Torres O.Fuentes:scopus